Secukinumab shows sustained efficacy in difficult-to-treat palmoplantar, nail, and scalp psoriasis: Long-term results from three phase III placebo-controlled randomized trials

Introduction: Psoriasis is a chronic, autoimmune inflammatory condition that can affect different parts of the body including scalp, nails, palms and soles. Psoriasis localized in these areas remains difficult-to-treat, and can result in significant physical and psychosocial disability. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis, demonstrating a rapid onset of action and sustained responses up to 5 years with a favorable safety profile.